Evolution of laboratory markers for systemic bacterial infections


Cite item

Full Text

Abstract

The paper reviews the data available in the literature on existing laboratory markers for systemic bacterial infection, among which C-reactive protein, proinflammatory cytokines, procalcitonin test, and presepsin receive primary emphasis.

About the authors

N L Ryabkova

ФГБОУ ВО «Петрозаводский государственный университет»

Петрозаводск, Россия

N N Vezikova

ФГБОУ ВО «Петрозаводский государственный университет»

Петрозаводск, Россия

References

  1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165-228. https://doi.org/10.1007/s00134-012-2769-8
  2. Pasqualini L, Mencacci A, Leli C, Montagna Р, Cardaccia А, Cenci Е, Montecarlo I, Pirro М, Filippo F, Cistaro Е, Schillaci G, Bistoni F, Mannarino Е. Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. J Clin Microbiol. 2012;50(4):1285-1288. https://doi.org/10.1128/JCM.06793-11
  3. French K, Evans J, Tanner H, Gossain S, Hussain A. The clinical impact of rapid, direct MALDI-ToF identification of bacteria from positive blood cultures. PLoS One. 2016;11(12):e0169332. https://doi.org/10.1371/journal.pone.0169332
  4. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск: МАКМАХ; 2007.
  5. Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии. Российские национальные рекомендации. Москва, 2010. Вестник анестезиологии и реаниматологии. 2011;8(3):55-63.
  6. Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа; 2008.
  7. Dupuy AM, Philippart F, PÉan Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE, Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J, Gauzit R, Misset B, Brun-Buisson C. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I — currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3(1):22. https://doi.org/10.1186/2110-5820-3-22
  8. Pizzolato Е, Ulla M, Galluzzo С, Lucchiari M, Manetta T, Lupia E, Mengozzi G, Battista S. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med. 2014;52(10):1395-1400. https://doi.org/10.1515/cclm-2014-0199
  9. Kaya Z, Küҁükcongar А, Vurallı D, Emeksiz HC, Gürsel T. Leukocyte populations and C-reactive protein as predictors of bacterial infections in febrile outpatient children. Turk J Haematol. 2014;31(1):49-55. https://doi.org/10.4274/Tjh.2013.0057
  10. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-137. https://doi.org/10.7326/0003-4819-128-2-199801150-00009
  11. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence. 2014; 5(1):154-160. https://doi.org/10.4161/viru.27393
  12. Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala EM. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scand J Infect Dis. 2011;43:883-890. https://doi.org/10.3109/00365548.2011.600325
  13. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32:2173-2182. https://doi.org/10.1097/01.CCM.0000145229.59014.6C
  14. Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure? Curr Opin Infect Dis. 2012;25:328-336. https://doi.org/10.1097/QCO.0b013e3283522038
  15. Kojic D, Siegler BH, Uhle F, Lichtenstern C, Nawroth PP, Weigand MA, Hofer S, Brenner T. Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis? World J Exp Med. 2015;5(2):50-63. https://doi.org/10.5493/wjem.v5.i2.50
  16. Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, Carstina D, Oltean M. Multiplex cytokine profiling in patients with sepsis. APMIS. 2011;119(2):155-163. https://doi.org/10.1111/j.1600-0463.2010.02705.x
  17. Gatserelia L, Sharvadze L, Karchava M, Babridze N, Tsevadze T, Dvali N, Dzigua L, Chxartishvili N. Procalcitonin as a marker of bacterial sepsis inimmunocompromised patients. Retrovirology. 2012;9(suppl.1):P90. https://doi.org/10.1186/1742-4690-9-S1-P9
  18. Gómez-Cerquera JM, Daroca-PÉrez R, Baeza-Trinidad R, Casañas-Martinez M, Mosquera-Lozano JD, Ramalle-Gómara E. Validity of procalcitonin for the diagnosis of bacterial infection in elderly patients. Enferm Infecc Microbiol Clin. 2015;33(8):521-524. https://doi.org/10.1016/j.eimc.2014.10.019
  19. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Critical Care. 2007;11(2):R38. https://doi.org/10.1186/cc5723
  20. Leroy S, Fernandez-Lopez A, Nikfar R, Romanello C, Bouissou F, Gervaix A, Gurgoze MK, Bressan S, Smolkin V, Tuerlinckx D, Stefanidis CJ, Vaos G, Leblond P, Gungor F, Gendrel D, Chalumeau M. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric urinary tract infections. Pediatrics. 2013; 131:870-879. https://doi.org/10.1542/peds.2012-2408
  21. Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T, Ito S, Otani H, Abe A, Ishikawa H, Nakazono K, Kuroda T, Nakano M, Narita I. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol. 2012;39:1517-1523. https://doi.org/10.3899/jrheum.111601
  22. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206-217. https://doi.org/10.1086/421997
  23. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996-2003. https://doi.org/10.1097/01.CCM.0000226413.54364.36
  24. Pourakbari B, Mamishi S, Zafari J, Khairkhah H, Ashtiani MH, Abedini M, Afsharpaiman S, Rad SS. Evaluation of procalcitonin and neopterin level in serum of patients with acute bacterial infection. Braz J Infect Dis. 2010;14(3):252-255.
  25. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med. 2013;28:285-291. https://doi.org/10.3904/kjim.2013.28.3.285
  26. Вельков В.В. Комплексная лабораторная диагностика системных инфекций и сепсиса: С-реактивный белок, прокальцитонин, пресепсин. 2015. Ссылка активна на 06.01.2017. Доступно по: http://www.diakonlab.ru/files/ComplexLabDiagVVV2014.pdf
  27. Mohkam M, Kompani F, Ghafari A. Diagnostic values of serum procalcitonin in kidney diseases. J Ped Nephrology. 2015;3(1):7-12.
  28. Aggarwal S, Schauer M. Not every rise in procalcitonin is infection. J Case Rep Stud. 2013;1(2):203. https://doi.org/10.15744/2348-9820.1.203
  29. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care. 2013;17(5):R244. https://doi.org/10.1186/cc13070
  30. Ramana KV, Pinnelli VBK, Kandi S, Asha G, Jayashankar CA, Bhanuprakash, Raghavendra DS, Sanjeev D. Presepsin: a novel and potential diagnostic biomarker for sepsis. American Journal of Medical and Biological Research. 2014;2(4):97-100. https://doi.org/10.12691/ajmbr-2-4-3
  31. Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D, Grosen E, Tiggelaar CL, Spriggs D, Gillis W, d’Oleire F. Cytokine induction in human by 41.8 degrees C whole body hyperthermia. Cancer Lett. 1995;97:195-201.
  32. Dornbusch HJ, Strenger V, Sovinz P, Lackner H, Schwinger W, Kerbl R, Urban C. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer. 2008;16(9):1035-1040. https://doi.org/10.1007/s00520-007-0381-1
  33. Leroy S, Fernandez-Lopez A, Nikfar R, Romanello C, Bouissou F, Gervaix A, Gurgoze MK, Bressan S, Smolkin V, Tuerlinckx D, Stefanidis CJ, Vaos G, Leblond P, Gungor F, Gendrel D, Chalumeau M. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric urinary tract infections. Pediatrics. 2013;131:870-879. https://doi.org/10.1542/peds.2012-2408
  34. Gartzonika C, Priavali E, Zotos N, Kallinteri A, Katsoula I, Sakkas H, Papapetrou E, Kapsali E, Vrioni G, Mavridis A, Nakos G, Levidiotou S. Serum procalcitonin as a diagnostic tool of bacteremia. Crit Care. 2010;14(suppl.2):P14. https://doi.org/10.1186/cc9117
  35. Mohan A., Harikrishna J. Biomarkers for the diagnosis of bacterial infections: in pursuit of the «Holy Grail» (Commentary). Indian J Med Res. 2015;141(3):271-273.
  36. Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY, Chan RC, Lee CC, Chang SS. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034-3042. https://doi.org/10.1002/art.34512
  37. Boysen AK, Jensen BR, Poulsen LØ, Jensen P. Procalcitonin as a marker of infection in febrile neutropenia: a systematic review. Modern Chemotherapy. 2013:2;8-14. https://doi.org/10.4236/mc.2013.21002
  38. Henriquez-Camacho C, Losa J. Biomarkers for Sepsis. Biomed Res Int. 2014;2014:547818. https://doi.org/10.1155/2014/547818
  39. Kogata, Yoshinori, Sugiyama, Daisuke, Onishi, Akira, Naka, Ikuko, Tsuda, Kosaku, Nishimura, Keisuke, Misaki, Kenta. A meta-analysis: diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with rheumatic diseases. Arthritis Rheum. 2011;63(suppl.10):1057.
  40. Li H, Luo YF, Blackwell TS, Xie CM. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother. 2011;55(12):5900-5906. https://doi.org/10.1128/AAC.00335-11
  41. Lv B, Huang J, Yuan H, Yan W, Hu G, Wang J. Tumor necrosis factor-as a diagnostic marker for neonatal sepsis: a meta-analysis. Scientific World Journal. 2014;2014:471463. https://doi.org/10.1155/2014/471463
  42. Qu J, Lü X, Liu Y, Wang X. Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients. Indian J Med Res. 2015;141(3):315-321.
  43. Su H, Chang SS, Han CM, Wu KY, Li MC, Huang CY, Lee CL, Wu JY, Lee CC. Inflammatory markers in cord blood or maternal serum for early detection of neonatal sepsis — a systemic review and meta-analysis. J Perinatol. 2014;34(4):268-274. https://doi.org/10.1038/jp.2013.186
  44. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435. https://doi.org/10.1016/S1473-3099(12)70323-7
  45. Anevlavis S, Kaltsas K, Bouros D. Procalcitonin as a marker of bacterial infection in elderly patients. Pneumon. 2014;27(1):13-15.
  46. Lee SH, Chan RC, Wu JY, Chen HW, Chang SS, Lee CC. Diagnostic value of procalcitonin for bacterial infection in elderly patients — a systemic review and meta-analysis. Int J Clin Pract. 2013;67(12):1350-1357. https://doi.org/10.1111/ijcp.12278
  47. Summah H, Tao LL, Zhu YG., Jiang HN, Qu JM. Pleural fluid soluble triggering receptor expressed on myeloid cells-1 as a marker of bacterial infection: a meta-analysis. BMC Infect Dis. 2011;11:280. https://doi.org/10.1186/1471-2334-11-280
  48. Abednazari H, Brudin L, Almroth G, Nilsson I, Nayeri F. Hepatocyte growth factor is a reliable marker for efficient anti-bacterial therapy within the first day of treatment. Advances in Bioscience and Biotechnology. 2014;5(5):823-830. https://doi.org/10.4236/abb.2014.510096
  49. Fjaertoft G, Håkansson LD, Pauksens K, Sisask G, Venge P. Neutrophil CD64 (FcɣRI) expression is a specific marker of bacterial infection: a study on the kinetics and the impact of major surgery. Scandinavian Journal of Infectious Diseases. 2007;39:525-535.
  50. Wang X, Li ZY, Zeng L, Zhang AQ, Pan W, Gu W, Jiang JX. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Crit Care. 2015;19:245. https://doi.org/10.1186/s13054-015-0972-z
  51. Cid J, Aguinaco R, Sánchez R, García-Pardo G, Llorente A. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. J Infect. 2010;60(5):313-319. https://doi.org/10.1016/j.jinf.2010.02.013
  52. Gibot S, BÉnÉ MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, Bittencourt M, Queno J, Bollaert P, Faure G, Charles P. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med. 2012;186(1):65-71. https://doi.org/10.1164/rccm.201201-0037OC
  53. AbdAllah TH, El-Reweny EM, El-Sawy MM, Aboudeif MM. Prognostic value of presepsin (soluble CD14 subtype) in critically ill patients with severe sepsis and septic shock. Life Sci J. 2015;12(1):134-141.
  54. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5(1):16-19. https://doi.org/10.5847/wjem.j.1920-8642.2014.01.002
  55. Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, Yamashita K. Phagocytosis by human monocytes is required for the secretion of presepsin. J Infect Chemother. 2015;21(8):564-569. https://doi.org/10.1016/j.jiac.2015.04.011
  56. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgrò S, Fanizza C, Romero M, Tognoni G, Latini R, Gattinoni L. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18(1):R6. https://doi.org/10.1186/cc13183
  57. Makarova P, Galstyan G, Krechetova A et al. Usefulness of presepsin (PSP) for assessment of sepsis in leukopeniс patients (pts. Abstracts from the 27th Annual Congress, ESICM LIVES 2014, 27 September-1 October, 2014, Barcelona, Spain. https://doi.org/10.1007/s00134-013-3451-5 Accessed January 06, 2017. Available at: http://react-profile.org/Download/ESICM2014_Abstract_Book_final_version.pdf
  58. Tsuji S, Ohshima S, Yura A, Katayama M, Watanabe A, Teshigawara S, Yoshimura M, Tanaka E, Harada Y, Katada Y, Matsushita M, Taura A, Kitatoube A, Takahashi G, Endo S, Hashimoto J, Saeki Y. Serum presepsin (soluble CD14-subtype) as a novel useful biomarker for infection in patients with rheumatoid arthritis (RA). Ann Rheum Dis. 2013;72(suppl.3):A314. https://doi.org/10.1136/annrheumdis-2013-eular.970
  59. Maravic-Stojkovic V, Lausevic-Vuk Lj, Jovic M, Filipovic M, Bojic Milinovic T, Stojkovic B, Isenovic RE, Djukanovic B. Levels of presepsin and midregion-proadrenomedullin in septic patients with end-stage renal disease after cardiovascular surgery: 1-year follow up study. J Clin Exp Cardiolog. 2014;5:4. https://doi.org/10.4172/2155-9880.1000307
  60. Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS One. 2015;10(7):e0133057. https://doi.org/10.1371/journal.pone.0133057
  61. Ackland GL, Prowle JR. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med. 2015;41(2):351-353. https://doi.org/10.1007/s00134-014-3642-8

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies